Illumina CEO Predicts Routine Tumor Sequencing, Infant Genome Screening within Next Decade

At the Consumer Genetics conference in Boston last week, Illumina CEO Jay Flatley made a number of predictions of where whole-genome sequencing and the consumer genetics industry are headed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.